tbuckley/cabot-search huggingface dataset:
Abstract PS2-39: A peninsular experience - developing a non-biopsy protocol for the female cohort 25-29 years with clinically typical fibroadenoma conforming to maxwell criteria on ultrasound
Authors: Tahera Arif, Mohammed Shameem Absar, Raman Vinayagam
Journal: Cancer Research (2021)

Abstract Abstract.Abstract1: IntroAim: The aim of this study was to introduce a non -biopsy protocol in our department for benign breast lump referrals confirmed as typical U2/3 fibroadenoma on imaging. The cohort of women between 25-29 years of age with sonographic features (Maxwell non-biopsy criteria) U2/3 typical of fibroadenoma does not miss malignancy. Current UK guidance is not to biopsy sonographically typical fibroadenomas in women under 25 years. We have studied our population extending the radiological Maxwell criteria reflecting histologically benign outcomes even in this group of 25-29 years.MethodsMethods: Retrospectively data was collected of all women between 25-29 years of age undergoing core biopsy for ultrasound confirmed both simple and complex fibroadenomas at Clatterbridge General Hospital between 2014 and 2019 over a period of five years. The number of cancers picked up was compared with the number of referrals and the discordance between radiological diagnosis of fibroadenoma and histopathological confirmation of malignancy was recorded.ResultsResults: We saw increment in referrals in this group of young women from n=260 to n=386 over the five year study period. A total of 1707 referrals were made across five years. n=175 image guided core biopsies were carried out for U2,U3,U4 lesions appearing as fibroadenoma on ultrasound. Out of these (n=175), all lesions coded U2/3 (n=165) based on Maxwell criteria on ultrasound were negative for cancer. U4 lesions on ultrasound were confirmed as cancers mimicking fibroadenoma(n=10).ConclusionConclusion: This retrospective audit of 1707 patients provides sound evidence for safe non-biopsy of typical fibroadenomas in women 25-29 years when clinical and sonographic features meet strict criteria. We started using the non-biopsy protocol using Maxwell criteria for U2/3 lesions. We discharged women in this group if they met all the protocol criteria, i.e., their lesion does not appear suspicious clinically, has all the ultrasound appearances typical of a fibroadenoma U2/3, and they do not have any compounding circumstances (e.g., family history, genetic predisposition). As routine, we advise all women who are discharged without follow-up to examine their breasts regularly and return if they detect any changes including increase in lesion size. We need data to be audited prospectively and provide level 1 evidence to the same effect. Citation Format: Tahera Arif, Mohammed Shameem Absar, Raman Vinayagam. A peninsular experience - developing a non-biopsy protocol for the female cohort 25-29 years with clinically typical fibroadenoma conforming to maxwell criteria on ultrasound [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS2-39.
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19
Authors: Christine Hum, Julia Loiselle, Nadine Ahmed, Tyler A. Shaw, Caroline Toudic, John Paul Pezacki
Journal: Drugs (2021)

Coronaviruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 (COVID-19) pandemic, present a significant threat to human health by inflicting a wide variety of health complications and even death. While conventional therapeutics often involve administering small molecules to fight viral infections, small non-coding RNA sequences, known as microRNAs (miRNAs/miR-), may present a novel antiviral strategy. We can take advantage of their ability to modulate host-virus interactions through mediating RNA degradation or translational inhibition. Investigations into miRNA and SARS-CoV-2 interactions can reveal novel therapeutic approaches against this virus. The viral genomes of SARS-CoV-2, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) were searched using the Nucleotide Basic Local Alignment Search Tool (BLASTn) for highly similar sequences, to identify potential binding sites for miRNAs hypothesized to play a role in SARS-CoV-2 infection. miRNAs that target angiotensin-converting enzyme 2 (ACE2), the receptor used by SARS-CoV-2 and SARS-CoV for host cell entry, were also predicted. Several relevant miRNAs were identified, and their potential roles in regulating SARS-CoV-2 infections were further assessed. Current treatment options for SARS-CoV-2 are limited and have not generated sufficient evidence on safety and efficacy for treating COVID-19. Therefore, by investigating the interactions between miRNAs and SARS-CoV-2, miRNA-based antiviral therapies, including miRNA mimics and inhibitors, may be developed as an alternative strategy to fight COVID-19.
Abstract 13748: Volume-Pressure Loop Assessment of Changes in Left Atrial Function by Radiofrequency Catheter or Cryoballoon Ablation of Paroxysmal Atrial Fibrillation
Authors: Antonios Karanasos, Konstantinos Toutouzas, Kostas Tyrovolas, Dimitris Tsiachris, Michael Efremidis, Athanasios Kordalis, Maria Karmpalioti, Constantina Aggeli, Christodoulos Stefanadis, Dimitrios Tousoulis
Journal: Circulation (2019)

Introduction: Both radiofrequency (RF) catheter and cryoballoon are established methods for catheter ablation of paroxysmal atrial fibrillation (PAF). We evaluated changes in left atrium (LA) funct...
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
Authors: Yukimasa Shiotsu, Leonard M. Neckers, Ivo Wortman, Won G. An, Theodor W. Schulte, Shiro Soga, Chikara Murakata, Tatsuya Tamaoki, Shiro Akinaga
Journal: Blood (2000)
Helen Salisbury: Debts of gratitude
Authors: Helen Salisbury
Journal: BMJ (2021)

Sometimes my day is brightened by someone’s gratitude. Even if I barely remember the consultation referred to in a card, clearly it was appreciated by the patient. If I’m thanked in person I often respond, quite truthfully, that I was just doing my job. Conversely, most GPs have experiences of patients for whom they’ve gone the extra mile—with hours spent on long consultations, referrals, and advocacy—and received not gratitude but vocal dissatisfaction and sometimes formal complaints.

As a patient, I too have felt grateful to individual clinicians who have found the right words at the right time, who have been gentle and kind. But …
Abstract 15213: Association of Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and Covid-19 Infection Among Patients With Hypertension
Authors: Jaejin An, Rong Wei, hui zhou, Tiffany Luong, Ran Liu, Michael K Gould, Matthew Mefford, Teresa N Harrison, Beth Creekmur, Ming-Sum Lee, John J Sim, Jeffrey W Brettler, John P Martin, Angeline L Ong, Kristi Reynolds
Journal: Circulation (2020)

Introduction: Given the limited evidence, we investigated the association between use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and risk of Covid-19 infection within a large diverse hypertension population. Methods: We identified patients with hypertension as of March 1, 2020 (index date) from Kaiser Permanente Southern California, a large US integrated healthcare system. Patient demographics, antihypertensive medication use, neighborhood income and education, and comorbidities were identified from electronic health records within 1-year pre-index date. The study outcome was a positive RT-PCR test for Covid-19 between March 1 - May 6, 2020. We used multivariable logistic regression models to examine the association between ACEI/ARB use and Covid-19 infection. Results: Among 824,650 patients with hypertension, 16,898 (2.0%) were tested for Covid-19. Of those tested, 1,794 (10.6%) had a positive result and 547 (30.5% of positive cases) were hospitalized within 14-days of testing positive. Of those tested, 4,878 (28.9%) were on ACEIs, 3,473 (20.6%) were on ARBs, and 4,177 (24.7%) were on other antihypertensive medication classes. Risk of covid-19 infection associated with ACEI use decreased with increasing age (P-interaction = 0.01). In age-stratified analyses, ACEI use was not statistically associated with increased risk of Covid-19 infection among the age groups of 18-39, 40-64, and 65-84 years but was associated with lower risk of Covid-19 among those aged ≥85 years ( Table ). Across all age groups, ARB use was not associated with increased risk of Covid-19, but non-white race, lower neighborhood income and education, and no antihypertensive medication use were associated with increased risk of Covid-19. Conclusions: ACEI nor ARB use was not associated with increased risk of Covid-19 infection. The decreased risk of Covid-19 infection among older adults using ACEIs warrants further investigation.
The Multifaceted Roles of KCC2 in Cortical Development
Authors: Mari A. Virtanen, Pavel Uvarov, Martina Mavrovic, Jean Christophe Poncer, Kai Kaila
Journal: Trends in Neurosciences (2021)

KCC2, best known as the neuron-specific chloride-extruder that sets the strength and polarity of GABAergic currents during neuronal maturation, is a multifunctional molecule that can regulate cytoskeletal dynamics via its C-terminal domain (CTD). We describe the molecular and cellular mechanisms involved in the multiple functions of KCC2 and its splice variants, ranging from developmental apoptosis and the control of early network events to the formation and plasticity of cortical dendritic spines. The versatility of KCC2 actions at the cellular and subcellular levels is also evident in mature neurons during plasticity, disease, and aging. Thus, KCC2 has emerged as one of the most important molecules that shape the overall neuronal phenotype.
Abstract PS7-64: Breast cancer in young women in a tertiary-level hospital in Guatemala
Authors: Juan F Alvarado-Muñoz, Agatha Reyes-Morales, Alba J Kihn-Alarcón, Marco Chivalan, Silvana Torselli, Victor Puac-Polanco
Journal: Cancer Research (2021)

Abstract Background: Breast cancer is the frequent neoplasia in young women, which in developing countries is associated with more adverse outcomes. In Latin America, reports have shown an increased incidence of breast cancer in young women. No information exist regarding breast cancer characteristics in young Guatemalan women. We aimed to describe the clinical-pathological features among women aged 45 years or less treated in a tertiary-level hospital in Guatemala. Methods: We examined data from 119 women aged 45 years or less diagnosed with primary invasive breast cancer at the Oncology Unit Roosevelt Hospital in Guatemala between 2016 and 2020. Data were drawn from medical files on sociodemographic characteristics, histology, clinical stage, and breast cancer subtypes.Results: Of the total sample, breast cancer in women aged 45 years or less represented 31.2% of the cases. Of these, 24.36% is before 35 years, 28.57% between 35 to 39 years, and 47.05% between 39 to 45 years. Advanced clinical stages affected 66.6% of young women (48.33% for stages III and 18.33% stage IV). Data from specific breast cancer molecular subtype showed that 72.35% of cases in young women expressed an aggressive molecular subtype (Her-2 positive 27.06%, triple-negative 21.76%, and luminal/Her-2 positive 23.53%). Regarding treatment, most young patients received surgical treatment, as well as neoadjuvant or adjuvant chemotherapy. Only 24.37% received hormonal and 26.89% radiation therapy. Conclusions: Our finding suggested that young women treated for breast cancer at a tertiary-level hospital in Guatemala had a high proportion of aggressive molecular subtypes and a high rate of locally advanced disease. This aggressive cancer behavior among young women is consistent with findings in other Latin American countries. Evidence examining risk factors for aggressive cancer in young women, such as delay in diagnosis and treatment timing, is warranted. Table 1. Distributions of socio-demographic and cancer-related characteristics variables% (SE)n = 119ETHNIC GROUPMayan Indigenous12.61 (3.05)No-Mayan Indigenous87.39 (3.05)HISTOLOGYDuctal96.64 (1.66)Lobular1.68 (1.18)Other1.68 (1.18)CLINICAL STAGE*I1.67 (1.17)II31.67 (4.26)III48.33 (4.58)IV18.33 (3.54)BREAST CANCER SUBTYPELuminal27.65 (4.76)Her2 positive27.06 (5.11)Triple-negative21.76 (5.05)Luminal/Her223.53 (6.61)TREATMENTSurgery55.46 (4.58)Neoadjuvant Chemotherapy82.35 (3.51)Adjuvant Chemotherapy47.06 (4.59)Radiotherapy26.89 (4.08)Hormonotherapy24.37 (3.95) Citation Format: Juan F Alvarado-Muñoz, Agatha Reyes-Morales, Alba J Kihn-Alarcón, Marco Chivalan, Silvana Torselli, Victor Puac-Polanco. Breast cancer in young women in a tertiary-level hospital in Guatemala [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-64.
Promoting Equity in Eligibility for Registration on the Kidney Transplantation Waiting List: Looking beyond eGFRcr
Authors: Andrew S. Levey, Lesley A. Inker, Nitender Goyal
Journal: Journal of the American Society of Nephrology (2021)

Racial disparities in access to kidney transplantation in the United States are well known, with non-Hispanic Blacks having 65% lower access to transplantation compared with non-Hispanic Whites in the first year after kidney failure with replacement therapy (KFRT).[1][1] Disparities exist at all
Detection of Nasal Solitary Extramedullary Plasmacytoma on 18F-FDG PET/CT Imaging
Authors: Junhao Wu, Zijuan Rao, Guohao Jiang, Huipan Liu, Chunyin Zhang
Journal: Clinical Nuclear Medicine (2021)

A 46-year-old man presented with a 3-month history of epistaxis. CT and MRI scan showed a soft tissue mass in the left nasal cavity. An excisional biopsy of the mass revealed extramedullary plasmacytoma. 18F-FDG PET/CT showed intense activity in the region of the left nasal cavity but no other FDG-avid lesions. Additional workups did not reveal any evidence of systematic disease. Based on these findings, the patient was diagnosed as having solitary nasal extramedullary plasmacytoma. He received the local radiation therapy. During the 3-month follow-up, his symptom was relieved.
Abstract 17006: Tradeoff in Risks for Myocardial Infarction and Bleeding in Relation to Bleeding Risk: Insights From PARIS Registry
Authors: Sabato Sorrentino, Clayton Snyder, Usman Baber, Gennaro Giustino, Samantha Sartori, Serdar Farhan, Birgit Vogel, Jaya Chandrasekhar, Ge Zhen, David Cohen, Ariti Cono, Michael Gibson, Mitchell Krucoff, David Moliterno, Alaide Chieffo, Henry Timothy, Giora Weisz, Antonio Colombo, Ioannis Iakovou, Thomas Stuckey, Annapoorna Kini, Bernhard Witzenbichler, Philippe Gabriel Steg, George Dangas, Stuart Pocock, Roxana Mehran
Journal: Circulation (2017)

Introduction: There are limited data on the uptake of guideline directed medical therapy (GDMT) and the specific impact of high bleeding risk (HBR) on ischemic outcomes following PCI. Hypothesis: t...
Basal‐In Phenotypes: Cancer Cell Invasion of Mammary Organoids with Basal‐In Phenotype (Adv. Healthcare Mater. 4/2021)
Authors: Eric Parigoris, Soojung Lee, David Mertz, Madeleine Turner, Amy Y. Liu, Jason Sentosa, Sabra Djomehri, Hao Chen Chang, Kathryn Luker, Gary Luker, Celina G. Kleer, Shuichi Takayama
Journal: Advanced Healthcare Materials (2021)

Article number 2000810 by Shuichi Takayama and co-workers describes the basal-in phenotype of organotypic structures formed from MCF10A cells, in which a cell-produced basement membrane is located on the interior side of the organoid. Because of the conveniently located apical surface, represented by the region exposed to the media surrounding the organoid, this platform shows promise as a high throughput cancer invasion assay.
Abstract 12976: Higher Triglyceride Level is Associated With Higher Frequency of Macrophage Accumulation in Coronary Plaques
Authors: Kiyoshi Asakura, Yoshiyasu Minami, Masahiro Katamine, Ayami Kato, Aritomo Katsura, Toshimitsu Sato, Yusuke Muramatsu, Takuya Hashimoto, RYO KAMEDA, Kentaro Meguro, Takao Shimohama, Junya Ako
Journal: Circulation (2020)

Introduction: The impact of high triglyceride (TG) level on the characteristics of coronary plaque remains to be elucidated. Hypothesis: Higher TG level is associated with higher prevalence of vulnerable coronary plaque in patients with coronary artery disease (CAD). Methods: A total of 865 consecutive patients who underwent optical coherence tomography (OCT) imaging of the culprit lesion were included. Patients were classified into either the higher TG group (non-fasting TG ≥ 200 mg/dL, n=150) or the lower TG group (non-fasting TG &lt; 200 mg/dL, n=715). The morphologies of culprit plaque assessed by OCT were compared between the two groups. Results: The median (interquartile range) of TG in the 2 groups was 265.5 (221.5 – 314.8) mg/dL and 115.0 (84.0 – 152.0) mg/dL, respectively. The frequency of macrophage accumulation was significantly higher in the higher TG group than the lower TG group (41 vs. 33%, p=0.043) (Panel A), whereas the prevalence of other plaque components including thin-cap fibroatheroma (22 vs. 19%, p=0.386), microchannel (24 vs. 25%, p=0.907) and cholesterol crystal (23 vs. 23%, p=0.862) was comparable between the two groups. The incremental frequency of macrophage accumulation according to TG levels was observed (p=0.015, Panel B). Although the frequency of macrophage accumulation was comparable between the 2 groups among patients with a higher HDL cholesterol (HDL-C) level (&gt;35 mg/dL), macrophage accumulation was significantly more frequent in the higher TG group than in the lower TG group (71 vs. 41%, p=0.032) among patients with a lower HDL-C level (≤35 mg/dL). Conclusions: Higher TG level was associated with higher frequency of macrophage accumulation in culprit plaques in patients with CAD. The present results may partly explain the role of TG on the development of culprit plaque in coronary artery.
Abstract PS4-43: Prediction of breast ductal carcinoma in situ recurrence using histomics analysis of stromal features from hematoxylin and eosin stain-based images
Authors: Taman Upadhaya, Ronald Balassanian, Olivier Morin, Catherine Park
Journal: Cancer Research (2021)

Abstract OBJECTIVE It remains a challenge to predict individual risk for recurrence after primary treatment of ductal carcinoma in situ (DCIS). While DCIS is contained within the duct, prior studies have pointed to the importance of stromal collagen in cancer progression. Using hematoxylin and eosin (H&amp;E) stain-based images, we studied the collagen structure surrounding DCIS in a case-control cohort of women to determine whether stromal collagen could provide additional risk information. METHODS We present a quantitative histology image analysis pipeline (termed “histomics”) that consists of collagen segmentation, quantitative feature extraction and statistical analysis to predict recurrence. A cohort of 73 patients with DCIS (33 cases with recurrence matched with 40 controls) were retrospectively analyzed. H&amp;E images were obtained from pathologic slides and regions-of-interest (ROI) of the collagen in the stroma adjacent to DCIS was automatically segmented using an in-house trained deep learning algorithm. A total of 123 histomics features (intensity, statistical and textural) were then extracted from the segmented ROI for each patient. Kruskal-Wallis test and receiver-operating characteristic methodology was used to assess performance of the features to differentiate patients with and without recurrence. RESULTS We found substantial variations in recorded H&amp;E signal between samples, and the intensity and statistical features did not reach statistical significance. However, twelve percent of the textural features had an AUC between 0.62 to 0.61 with p-value between 0.06 to 0.08. Two textural histomics features in particular were significantly associated with DCIS patient recurrence; inverse variance (AUC: 0.64, p-value: 0.046) feature based on grey-level cooccurrences matrix (GLCM) and complexity (AUC 0.65, p-value: 0.025) feature based on neighborhood grey tone difference matrix (NGTDM). CONCLUSION Textural stromal features extracted from H&amp;E image-based histomics indicate association of some features with tumor progression in DCIS. H&amp;E image based histomics features can be a promising quantitative tool to develop predictive signatures of recurrence in patients with DCIS. We are processing additional patients through our quantitative image analysis pipeline to determine the significance of histomics features compared to conventional clinical features for the prediction of DCIS recurrence. Citation Format: Taman Upadhaya, Ronald Balassanian, Olivier Morin, Catherine Park. Prediction of breast ductal carcinoma in situ recurrence using histomics analysis of stromal features from hematoxylin and eosin stain-based images [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS4-43.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial
Authors: William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan Targan, Subrata Ghosh, Willem J.S. de Villiers, Jean-Frederic Colombel, Brian G. Feagan, John P. Lynch
Journal: Clinical Gastroenterology and Hepatology (2021)

The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn's disease. Here, we report the final results of IM-UNITI LTE through 5 years.Patients completing safety and efficacy evaluations at week 44 of the maintenance study were eligible to participate in the LTE and continue the treatment they were receiving. Unblinding occurred after completion of maintenance study analyses (August 2015), and patients receiving placebo were discontinued from the study after unblinding. No dose adjustment occurred in the LTE. Efficacy assessments were conducted every 12 weeks until unblinding and at dosing visits thereafter through week 252. Serum ustekinumab concentrations and antidrug antibodies were evaluated through weeks 252 and 272, respectively.Using an intent-to-treat analysis of all patients randomized to ustekinumab at maintenance baseline, 34.4% of patients in the every-8-weeks group and 28.7% in the every-12-weeks group were in clinical remission at week 252. Corresponding remission rates among patients who entered the LTE were 54.9% and 45.2%. Overall, adverse event rates (per 100 patient-years) from maintenance week 0 through the final visit generally were similar in the placebo and combined ustekinumab groups for all adverse events (440.3 vs 327.6), serious adverse events (19.3 vs 17.5), infections (99.8 vs 93.8), and serious infections (3.9 vs 3.4). Serum ustekinumab concentrations were maintained throughout the LTE. Antidrug antibodies occurred in 5.8% of patients who received ustekinumab during induction and maintenance and continued in the LTE.Patients receiving subcutaneous ustekinumab maintained clinical remission through 5 years. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.